Utility of the virtual crossmatch in solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 14, Issue 6, 2009, Pages 656-661

  Amico, Patrizia ^a   Hönger, Gideon ^a   Steiger, Jürg ^a   Schaub, Stefan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Complement dependent cytotoxicity crossmatch; Flow cytometric crossmatch; HLA antibodies, solid phase assays, virtual crossmatch

Indexed keywords

ALLOGRAFT; ANTIBODY SPECIFICITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CROSS REACTION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA SYSTEM; HLA TYPING; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MEMORY T LYMPHOCYTE; ORGAN DONOR; ORGAN TRANSPLANTATION; PREDICTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANTIBODIES; ANTIBODY SPECIFICITY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; ORGAN TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 74349087312     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328331c169     Document Type: Review

References (42)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
2. Gebel HM, Bray RA, Nickerson P. Pretransplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3:1488-1500.
3. Bearden CM, Agarwal A, Book BK, et al. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 2004; 65:803-809.
4. Wen R, Wu V, Dmitrienko S, et al. Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int 2006; 70:1474-1481.
5. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75:43-49.
6. Bielmann D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7:626-632.
7. Vaidya S, Partlow D, Susskind B, et al. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation 2006; 82:1524-1528.
8. Nikaein A, Cherikh W, Nelson K, et al. Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009; 87:557-562.
9. Bingaman AW,Murphey CL, Palma-Vargas J,Wright F. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86:1864-1868.
10. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6:2307-2315.
11. Zangwill SD, Ellis TM, Zlotocha J, et al. The virtual crossmatch - a screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006; 10:38-41.
12. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6:346-351.
13. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359:242-251.
14. Montgomery RA, Zachary AA. Transplanting patients with a positive donorspecific crossmatch: A single center's perspective. Pediatr Transplant 2004; 8:535-542.
15. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3:1160-1167.
16. Taylor CJ, Smith SI, Morgan CH, et al. Selective omission of the donor crossmatch before renal transplantation: Efficacy, safety and effects on cold storage time. Transplantation 2000; 69:719-723.
17. Gupta A, Iveson V, Varagunam M, et al. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008; 85:1200-1204.
18. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086-1090.
19. Amico P, Hönger G, Mayr M, et al. Clinical relevance of pretransplant donorspecific HLA antibodies detected by single antigen flow beads. Transplantation 2009; 87:1681-1688.
20. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pretransplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7:2371-2377.
21. Appel JZ III, Hartwig MG, Cantu E III, et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81:1049-1057.
22. Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87:549-556.
23. Zou Y, Stastny P, Susal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293-1300.
24. Alvarez-Marquez A, Aguilera I, Gentil MA, et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009; 87:94-99.
25. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
26. Tan JC, Wadia PP, Coram M, et al. H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation 2008; 86:75-81.
27. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to nonhuman leukocyte antigen-antibodies. Transplantation 2008; 85:1557-1563.
28. Goral S, Prak EL, Kearns J, et al. Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation. Nephrol Dial Transplant 2008; 23:390-392.
29. Vaidya S, Hilson B, Sheldon S, et al. DP reactive antibody in a zero mismatch renal transplant pair. Hum Immunol 2007; 68:947-949.
30. Kosmoliaptsis V, Bradley JA, Peacock S, et al. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009; 87:813-820.
31. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex1 assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009; 70:496-501.
32. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, et al. 'Natural' human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86:1111-1115.
33. El-Awar NR, Akaza T, Terasaki PI, Nguyen A. Human leukocyte antigen class I epitopes: Update to 103 total epitopes, including the C locus. Transplantation 2007; 84:532-540.
34. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8:324-331.
35. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86:820-825.
36. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8:2684-2694.
37. Bohmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13:411-418.
38. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9:998-1005.
39. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1:260-269.
40. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007; 84:876-884.
41. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8:2652-2660.
42. Duquesnoy RJ, Marrari M. HLAMatchmaker-based definition of structural human leukocyte antigen epitopes detected by alloantibodies. Curr Opin Organ Transplant 2009; 14:403-409.